Moderna (MRNA)
(Delayed Data from NSDQ)
$63.94 USD
-0.20 (-0.31%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $64.14 +0.20 (0.31%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth D Momentum F VGM
Price, Consensus and EPS Surprise
MRNA 63.94 -0.20(-0.31%)
Will MRNA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MRNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRNA
Moderna (MRNA) Stock Slides as Market Rises: Facts to Know Before You Trade
PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab
MRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck Loses Around $32B in 3 Months: Time to Sell the Stock?
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
Why Novavax is Gaining Ground in COVID-19 Vaccine Race
Other News for MRNA
Best And Worst Performers Since August 5, 2024
Moderna: Still Bullish View
Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis
10 Health Care Stocks With Whale Alerts In Today's Session
UBS highlights 30 stocks poised for potential moves after the Fed’s expected rate cut